{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:41:30Z","timestamp":1777934490708,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Platinum compounds are frequently used for the treatment of colorectal cancer as initial chemotherapy. Oxaliplatin is a third-generation platinum used for the treatment of stage III colorectal cancer and is associated with hypersensitivity reactions. The incidence of hypersensitivity reaction is approximately 12%, with 1\u20132% of patients developing moderate to severe reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 54-year-old male patient with stage III B colon cancer was diagnosed and chemotherapy with oxaliplatin was indicated by the oncology service. Within 20\u2009min of the first cycle of oxaliplatin, he developed dyspnea, laryngeal spam, foreign body sensation in the throat, nausea, and diarrhea; therefore, the infusion of oxaliplatin was suspended, and intramuscular epinephrine was administered and intravenous hydrocortisone along with chlorpheniramine with adequate resolution of symptoms.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Management and outcome:<\/jats:bold>\n                      Intradermal skin test performed at the concentration of 5\u2009mg\/ml (dilution 1:100) was positive. Due to the symptoms presented we decided to perform desensitization to oxaliplatin (total dose: 250\u2009mg) with three bags\u201312 steps protocol with an initial concentration dose of 1\/100 of the total dose in a course of 5.56\u2009h with no hypersensitivity reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Approximately 50% of patients who are exposed to oxaliplatin may have hypersensitivity despite premedication. Desensitization protocol induces tolerance to a drug temporarily and is dependent on continuous exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220939143","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T01:32:17Z","timestamp":1594171937000},"page":"490-493","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful oxaliplatin desensitization protocol in a patient with colorectal metastatic cancer"],"prefix":"10.1177","volume":"27","author":[{"given":"Cindy E.","family":"de Lira-Quezada","sequence":"first","affiliation":[{"name":"Regional Center of Allergy and Clinical Immunology, University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-6934","authenticated-orcid":false,"given":"Rosalaura V.","family":"Villarreal-Gonzalez","sequence":"additional","affiliation":[{"name":"Regional Center of Allergy and Clinical Immunology, University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra N.","family":"Gonzalez-Diaz","sequence":"additional","affiliation":[{"name":"Regional Center of Allergy and Clinical Immunology, University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligia L.","family":"Carrasco-Diaz","sequence":"additional","affiliation":[{"name":"Regional Center of Allergy and Clinical Immunology, University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01472"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2014.12.010"},{"key":"e_1_3_5_4_2","article-title":"Low cross-reactivity between cisplatin and other platinum salts","author":"Pasteur J","unstructured":"Pasteur J, Favier L, Pernot C, et\u00a0al. Low cross-reactivity between cisplatin and other platinum salts. J Allergy Clin Immunol Pract 2019; 7(6): 1894\u20131900.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.06.003"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2015.01.011"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2019.60.2.119"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0038"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv081"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1179\/1973947814Y.0000000204"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04863-5"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.12.032"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2017.05.016"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx216"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0326"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220939143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220939143","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220939143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:18Z","timestamp":1777688598000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220939143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/1078155220939143"],"URL":"https:\/\/doi.org\/10.1177\/1078155220939143","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}